Esperion announced positive Phase 2 pediatric study results showing bempedoic acid (NEXLETOL) safely reduced LDL-C by 6-25% in children aged 6-17 with familial hypercholesterolemia. Additionally, a secondary analysis of CLEAR Outcomes found that 42% of statin-intolerant patients achieved ≥30% LDL-C reduction at 3 months, with enhanced results in women, patients with higher baseline LDL-C, and those using concurrent ezetimibe.

Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties. The investigations concern Sila Realty Trust's sale to Blue Owl affiliates, Esperion Therapeutics' sale to ARCHIMED funds, and a merger between Corebridge Financial and Equitable Holdings. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.

Law firm Brodsky & Smith announced investigations into four merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Esperion Therapeutics (ARCHIMED acquisition at $3.16/share), Sila Realty Trust (Blue Owl Capital acquisition at $30.38/share), Lisata Therapeutics (Kuva Labs acquisition at $4.00/share plus CVRs), and SkyWater Technology (IonQ acquisition at $35.00/share).

Esperion Therapeutics (ESPR) shares rose on Monday following announcement of a $1.1 billion acquisition deal with Archimed. Shareholders will receive $3.16 per share in cash plus contingent value rights (CVRs) representing a 58% premium to the April 30 closing price. The CVRs include potential milestone payments up to $100 million based on future sales performance of bempedoic acid and bumetanide products through 2030. The transaction is expected to close soon.

Monteverde & Associates PC is investigating Esperion Therapeutics' proposed sale to ARCHIMED funds, where shareholders would receive $3.16 per share in cash plus contingent milestone payments. The investigation questions whether the deal terms are fair to shareholders.

Esperion Therapeutics announced a definitive agreement to be acquired by ARCHIMED for approximately $1.1 billion. Shareholders will receive $3.16 per share in cash at closing plus up to $100 million in contingent milestone payments, representing a 58% premium over the previous closing price. The stock surged 57.50% in premarket trading on Friday.

Athyrium Capital Management has agreed to a $50 million royalty financing deal with Esperion Therapeutics, acquiring royalty rights on Japan net sales of bempedoic acid products from Otsuka Pharmaceutical. The non-dilutive capital will support Esperion's acquisition of Corstasis Therapeutics, developer of Enbumyst™, the first FDA-approved intranasal loop diuretic. This marks Athyrium's second investment in Esperion within 16 months.

Esperion Therapeutics completed its acquisition of Corstasis Therapeutics, integrating Enbumyst (bumetanide nasal spray), the first FDA-approved nasal spray loop diuretic, into its cardiovascular portfolio. The acquisition is expected to drive portfolio expansion, leverage Esperion's existing commercial infrastructure, and support revenue growth in the treatment of edema associated with congestive heart failure and hepatic/renal disease.

Esperion Therapeutics has completed its acquisition of Corstasis Therapeutics, adding Enbumyst (bumetanide nasal spray) to its cardiovascular portfolio. Enbumyst is the first and only FDA-approved nasal spray loop diuretic for treating edema associated with congestive heart failure and hepatic/renal disease. Esperion plans to leverage its existing cardiovascular commercial infrastructure to drive adoption and revenue growth.

Esperion Therapeutics announced a definitive agreement to acquire Corstasis Therapeutics for $75 million upfront plus up to $180 million in milestone payments. The acquisition includes Enbumyst, the first FDA-approved nasal spray diuretic for congestive heart failure edema. Esperion shares fell 5.4% in premarket trading as the broader market declined. The company expects the deal to close in Q2 2026 and drive double-digit revenue growth.

Esperion announced a settlement agreement with Alkem Laboratories Ltd. to prevent the marketing of generic versions of NEXLETOL and NEXLIZET in the United States until April 19, 2040. This is the fifth ANDA filer to reach such an agreement with Esperion. Patent litigation against four remaining defendants (Aurobindo Pharma, MSN Pharmaceuticals, Renata Limited, and Sandoz Inc.) continues with uncertain outcomes.

Esperion announced that its partner Otsuka launched NEXLETOL in Japan, receiving a $90 million payment for the cardiovascular prevention drug's national health insurance price listing and market entry.